BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;. [PMID: 32997882 DOI: 10.1111/liv.14675] [Cited by in Crossref: 138] [Cited by in F6Publishing: 148] [Article Influence: 138.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Q, Zhao G, Li Q, Wu W, Zhang Y, Bian H. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study. BMC Gastroenterol 2022;22:471. [DOI: 10.1186/s12876-022-02576-4] [Reference Citation Analysis]
2 Rivera-iñiguez I, Panduro A, Roman S, González-aldaco K. What do we know about nutrient-based strategies targeting molecular mechanisms associated with obesity-related fatty liver disease? Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100874] [Reference Citation Analysis]
3 Perdomo CM, Núñez-córdoba JM, Ezponda A, Mendoza FJ, Ampuero J, Bastarrika G, Frühbeck G, Escalada J. Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease. Front Med 2022;9:1023583. [DOI: 10.3389/fmed.2022.1023583] [Reference Citation Analysis]
4 Seo JY, Cho EJ, Kim MJ, Kwak MS, Yang JI, Chung SJ, Yim JY, Yoon JW, Chung GE. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population. J Cachexia Sarcopenia Muscle 2022. [PMID: 36222309 DOI: 10.1002/jcsm.13099] [Reference Citation Analysis]
5 Ogasawara Y, Kogiso T, Horiuchi K, Taniai M, Tokushige K. Outcomes of fatty liver disease with and without metabolic comorbidities and risk factors for mortality.. [DOI: 10.21203/rs.3.rs-2110374/v1] [Reference Citation Analysis]
6 Torres L, Schuch A, Longo L, Valentini BB, Galvão GS, Bartels R, Reis Álvares-da-silva M. New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by Magnetic Resonance Elastography in NAFLD. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100774] [Reference Citation Analysis]
7 Kołakowski A, Dziemitko S, Chmielecka A, Żywno H, Bzdęga W, Charytoniuk T, Chabowski A, Konstantynowicz-nowicka K. Molecular Advances in MAFLD—A Link between Sphingolipids and Extracellular Matrix in Development and Progression to Fibrosis. IJMS 2022;23:11380. [DOI: 10.3390/ijms231911380] [Reference Citation Analysis]
8 García-Compeán D, Jiménez-Rodríguez AR. NAFLD VS MAFLD. The evidence-based debate has come. Time to change? Ann Hepatol 2022;:100765. [PMID: 36179795 DOI: 10.1016/j.aohep.2022.100765] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Liu Q, Zhao G, Li Q, Wu W, Zhang Y, Bian H. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China.. [DOI: 10.21203/rs.3.rs-1713068/v2] [Reference Citation Analysis]
10 Cheng Y, Wang C, Kao J. Metabolic Associated Fatty Liver Disease Better Identifying Patients at Risk of Liver and Cardiovascular Complications.. [DOI: 10.21203/rs.3.rs-2025707/v1] [Reference Citation Analysis]
11 Sarin SK, Eslam M, Fan JG, Lin HC, George J, Omata M. MAFLD, patient-centred care, and APASL. Hepatol Int 2022. [PMID: 36070122 DOI: 10.1007/s12072-022-10408-6] [Reference Citation Analysis]
12 Chen CL, Lin YC. Autophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target. Int J Mol Sci 2022;23:10055. [PMID: 36077452 DOI: 10.3390/ijms231710055] [Reference Citation Analysis]
13 Wang S, Wang P, Zhang Q, Luo T, Qin B. Effects of physical activity and diet quality on the prevalence and characteristics of obese and non-obese MAFLD in a US population.. [DOI: 10.21203/rs.3.rs-1965788/v1] [Reference Citation Analysis]
14 Tsutsumi T, Nakano D, Kawaguchi M, Hashida R, Yoshinaga S, Takahashi H, Anzai K, Kawaguchi T. MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men. Diabetol Metab Syndr 2022;14:115. [PMID: 35974418 DOI: 10.1186/s13098-022-00887-w] [Reference Citation Analysis]
15 Pal SC, Eslam M, Mendez-Sanchez N. Detangling the interrelations between MAFLD, insulin resistance, and key hormones. Hormones (Athens) 2022. [PMID: 35921046 DOI: 10.1007/s42000-022-00391-w] [Reference Citation Analysis]
16 Wang Q, Xue J, Shi M, Xie Y, Xiao H, Li S, Lin M, Chi X. Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cirrhosis in Patients with Chronic Hepatitis B—A Retrospective Cohort Study. DMSO 2022;Volume 15:2311-22. [DOI: 10.2147/dmso.s369824] [Reference Citation Analysis]
17 Sohouli MH, Fatahi S, Izze da Silva Magalhães E, Rodrigues de Oliveira B, Rohani P, Ezoddin N, Roshan MM, Hekmatdoost A. Adherence to a Paleolithic Diet in Combination With Lifestyle Factors Reduces the Risk for the Presence of Non-Alcoholic Fatty Liver Disease: A Case-Control Study. Front Nutr 2022;9:934845. [DOI: 10.3389/fnut.2022.934845] [Reference Citation Analysis]
18 Han AL, Lee HK. Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease. Metabolites 2022;12:664. [DOI: 10.3390/metabo12070664] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Eslam M, El-Serag HB, Francque S, Sarin SK, Wei L, Bugianesi E, George J. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35710982 DOI: 10.1038/s41575-022-00635-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Guo Y, Yang J, Ma R, Zhang X, Guo H, He J, Wang X, Cao B, Maimaitijiang R, Li Y, Peng X, Zhang S, Guo S. Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang. Nutrients 2022;14:2361. [PMID: 35745091 DOI: 10.3390/nu14122361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Moon JS, Hong JH, Jung YJ, Ferrannini E, Nauck MA, Lim S. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2022;33:424-42. [PMID: 35491295 DOI: 10.1016/j.tem.2022.03.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Sumida Y. Renaming from nonalcoholic fatty liver disease to metabolism dysfunction associated fatty liver disease: Pros and cons. Hepatol Res 2022;52:415-6. [PMID: 35591814 DOI: 10.1111/hepr.13762] [Reference Citation Analysis]
23 Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, Tan DJH, Lim WH, Lin SY, Huang D, Chan M, Khoo CM, Chew NWS, Kaewdech A, Chamroonkul N, Dan YY, Noureddin M, Muthiah M, Eslam M, Ng CH. Global Prevalence and Clinical Characteristics of Metabolic Associated Fatty Liver Disease. A Meta-Analysis and Systematic Review of 10,739,607 Individuals. J Clin Endocrinol Metab 2022:dgac321. [PMID: 35587339 DOI: 10.1210/clinem/dgac321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
24 Zeng J, Fan JG. From NAFLD to MAFLD: Not just a change in the name. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00125-4. [PMID: 35613992 DOI: 10.1016/j.hbpd.2022.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Kim H, Lee CJ, Ahn SH, Lee KS, Lee BK, Baik SJ, Kim SU, Lee JI. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. Dig Dis Sci 2022. [PMID: 35579799 DOI: 10.1007/s10620-022-07508-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Zou Y, Li Q, Gao J, Pan J, Ma J, Chen L, Lin J, Mo Y, Zhang X, Liu P, Dai L. Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort. Front Cardiovasc Med 2022;9:884636. [DOI: 10.3389/fcvm.2022.884636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhu C, Huang D, Ma H, Qian C, You H, Bu L, Qu S. High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease. Front Endocrinol 2022;13:848937. [DOI: 10.3389/fendo.2022.848937] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wang J, Liu S, Cao Q, Wu S, Niu J, Zheng R, Bie L, Xin Z, Zhu Y, Wang S, Lin H, Wang T, Xu M, Lu J, Chen Y, Xu Y, Wang W, Ning G, Xu Y, Li M, Bi Y, Zhao Z. New definition of metabolic dysfunction-associated fatty liver disease with elevated brachial-ankle pulse wave velocity and albuminuria: a prospective cohort study. Front Med 2022. [PMID: 35507246 DOI: 10.1007/s11684-021-0888-8] [Reference Citation Analysis]
29 Rui F, Yang H, Hu X, Xue Q, Xu Y, Shi J, Li J. Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management. Infectious Microbes and Diseases 2022;4:49-55. [DOI: 10.1097/im9.0000000000000089] [Reference Citation Analysis]
30 Shi YW, Fan JG. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1191-9. [PMID: 34907360 DOI: 10.1038/s41401-021-00822-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
31 Park H, Yoon EL, Kim M, Cho S, Nah EH, Jun DW. Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00437-2. [PMID: 35504562 DOI: 10.1016/j.cgh.2022.04.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Neri CR, Scapaticci S, Chiarelli F, Giannini C. Liver Steatosis: A Marker of Metabolic Risk in Children. Int J Mol Sci 2022;23:4822. [PMID: 35563210 DOI: 10.3390/ijms23094822] [Reference Citation Analysis]
33 Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents. Hepatol Commun 2022. [PMID: 35470984 DOI: 10.1002/hep4.1969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Xiong KG, Ke KY, Chen LF, Kong JF, Lin TS, Lin QB, Lin S, Zhu YY. The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00051-0. [PMID: 35466065 DOI: 10.1016/j.hbpd.2022.04.001] [Reference Citation Analysis]
35 Younossi ZM, Paik JM, Al Shabeeb R, Golabi P, Younossi I, Henry L. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology 2022. [PMID: 35363908 DOI: 10.1002/hep.32499] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
36 Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol 2022;7:388-90. [PMID: 35248211 DOI: 10.1016/S2468-1253(22)00062-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 30.0] [Reference Citation Analysis]
37 Tsutsumi T, Kawaguchi T, Nakano D, Torimura T. Atherosclerotic cardiovascular disease in non-metabolic nonalcoholic fatty liver disease. Hepatol Res 2022;52:317-9. [PMID: 35229393 DOI: 10.1111/hepr.13738] [Reference Citation Analysis]
38 Tang L, Ma H, Eslam M, Wong GL, Zhu P, Chen S, Leeming DJ, Karsdal M, Li G, Huang O, Leung HH, Zhou Y, Feng Q, Jiang P, Gao L, Byrne CD, Targher G, George J, Wong VW, Zheng M. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. Metabolism 2022;128:154958. [DOI: 10.1016/j.metabol.2021.154958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Yuan Q, Wang H, Gao P, Chen W, Lv M, Bai S, Wu J. Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China. IJERPH 2022;19:2096. [DOI: 10.3390/ijerph19042096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
40 Zhu C, Ma H, Huang D, Li G, Gao J, Cai M, You H, Bu L, Qu S. J-Shaped Relationship Between Serum Prolactin and Metabolic-Associated Fatty Liver Disease in Female Patients With Type 2 Diabetes. Front Endocrinol 2022;13:815995. [DOI: 10.3389/fendo.2022.815995] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Marc L, Mihaescu A, Lupusoru R, Grosu I, Gadalean F, Bob F, Chisavu L, Olariu N, Tucicovschi V, Timar B, Sporea I, Timar R, Schiller A. Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter. Front Med (Lausanne) 2021;8:788881. [PMID: 35096879 DOI: 10.3389/fmed.2021.788881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology 2022;75:419-29. [PMID: 34453359 DOI: 10.1002/hep.32131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
43 Chan WK, Wong VW. Meaning of non-overlapping patients between the MAFLD and NAFLD definitions. Liver Int 2022;42:271-3. [PMID: 35092337 DOI: 10.1111/liv.15142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Devi J, Raees A, Butt AS. Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible? World J Hepatol 2022; 14(1): 158-167 [DOI: 10.4254/wjh.v14.i1.158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Chen Y, Yang C, Chung C, Ho C, Chen W, Chien W. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study. Hepatol Int. [DOI: 10.1007/s12072-021-10281-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
46 Xie X, Guo B, Xiao X, Yin J, Wang Z, Jiang X, Li J, Long L, Zhou J, Zhang N, Zhang Y, Chen T, Kangzhuo B, Zhao X. Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study. BMC Public Health 2022;22:118. [PMID: 35038997 DOI: 10.1186/s12889-021-12486-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Lee H, Lee HW, Kim SU, Chang Kim H. Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study. Clin Transl Gastroenterol 2022. [PMID: 35080508 DOI: 10.14309/ctg.0000000000000435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
48 Gatzios A, Rombaut M, Buyl K, De Kock J, Rodrigues RM, Rogiers V, Vanhaecke T, Boeckmans J. From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights. Biomedicines 2022;10:161. [DOI: 10.3390/biomedicines10010161] [Reference Citation Analysis]
49 Wang TY, Wang RF, Bu ZY, Targher G, Byrne CD, Sun DQ, Zheng MH. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol 2022. [PMID: 35013596 DOI: 10.1038/s41581-021-00519-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 15.0] [Reference Citation Analysis]
50 Lee C. Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists? Primary Care Diabetes 2022. [DOI: 10.1016/j.pcd.2022.01.005] [Reference Citation Analysis]
51 Grabherr F, Grander C, Effenberger M, Schwärzler J, Tilg H. MAFLD: what 2 years of the redefinition of fatty liver disease has taught us. Therapeutic Advances in Endocrinology 2022;13:204201882211391. [DOI: 10.1177/20420188221139101] [Reference Citation Analysis]
52 Singh SP, Anirvan P, Khandelwal R, Satapathy SK. Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille? J Clin Transl Hepatol 2021;9:931-8. [PMID: 34966656 DOI: 10.14218/JCTH.2021.00174] [Reference Citation Analysis]
53 Santos-laso A, Gutiérrez-larrañaga M, Alonso-peña M, Medina JM, Iruzubieta P, Arias-loste MT, López-hoyos M, Crespo J. Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines 2022;10:46. [DOI: 10.3390/biomedicines10010046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Ayada I, van Kleef LA, Alferink LJM, Li P, de Knegt RJ, Pan Q. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups. Liver Int 2021. [PMID: 34953098 DOI: 10.1111/liv.15139] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 15.0] [Reference Citation Analysis]
55 Du X, DeForest N, Majithia AR. Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. Front Endocrinol (Lausanne) 2021;12:777075. [PMID: 34950105 DOI: 10.3389/fendo.2021.777075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Garbuzenko DV, Belov DV. Non-alcoholic fatty liver disease as an independent factor of cardiometabolic risk of cardiovascular diseases. jour 2021. [DOI: 10.31146/1682-8658-ecg-194-10-22-34] [Reference Citation Analysis]
57 Delgado ME, Cárdenas BI, Farran N, Fernandez M. Metabolic Reprogramming of Liver Fibrosis. Cells 2021;10:3604. [PMID: 34944111 DOI: 10.3390/cells10123604] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
58 Balvey A, Fernandez M. Translational Control in Liver Disease. Front Physiol 2021;12:795298. [PMID: 34912244 DOI: 10.3389/fphys.2021.795298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Cherubini A, Casirati E, Tomasi M, Valenti L. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets 2021;:1-11. [PMID: 34904923 DOI: 10.1080/14728222.2021.2018418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Rodríguez-Antonio I, López-Sánchez GN, Reyes-Gómez VA, Contreras-Flores EH, Farías-García F, Espejel-Deloiza M, Durán-Padilla MA, Chablé-Montero F, Uribe M, Chávez-Tapia NC, Montalvo-Javé EE, Nuño-Lámbarri N. Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis. Ann Hepatol 2021;27:100651. [PMID: 34896638 DOI: 10.1016/j.aohep.2021.100651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01276-3. [PMID: 34871813 DOI: 10.1016/j.cgh.2021.11.038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 16.0] [Reference Citation Analysis]
62 Lee SM, Jung YM, Choi ES, Kwak SH, Koo JN, Oh IH, Kim BJ, Kim SM, Kim SY, Kim GM, Joo SK, Koo BK, Shin S, Norwitz ER, Park CW, Jun JK, Kim W, Park JS. Metabolic Dysfunction-Associated Fatty Liver Disease and Subsequent Development of Adverse Pregnancy Outcomes. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01219-2. [PMID: 34798335 DOI: 10.1016/j.cgh.2021.11.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
63 Liu J, Wang G, Wu Y, Guan Y, Luo Z, Zhao G, Jiang Y. Early-Life Exposure to Famine and Risk of Metabolic Associated Fatty Liver Disease in Chinese Adults. Nutrients 2021;13:4063. [PMID: 34836318 DOI: 10.3390/nu13114063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Alharthi J, Eslam M. Metabolic associated fatty liver disease (MAFLD): a milestone in the history of fatty liver disease. Hepatobiliary Surg Nutr 2021;10:696-8. [PMID: 34760977 DOI: 10.21037/hbsn-21-269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Yang S, Cheng J, Zhang R, Sun H, Zhang H, Lyu S, Duan W. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. Hepatol Res 2021. [PMID: 34751487 DOI: 10.1111/hepr.13728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Tamaki N, Kurosaki M, Higuchi M, Izumi N. Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease. Hepatol Res 2021;51:1172-3. [PMID: 34724297 DOI: 10.1111/hepr.13700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Kodama T, Kozumi K, Takehara T. Issues regarding NAFLD~From the changes and problems in the pathological diagnosis of NASH to the confusion of nomenclature change. Acta hepatologica Japonica 2021;62:681-689. [DOI: 10.2957/kanzo.62.681] [Reference Citation Analysis]
68 Kamada Y, Takahashi H, Shimizu M, Kawaguchi T, Sumida Y, Fujii H, Seko Y, Fukunishi S, Tokushige K, Nakajima A, Okanoue T; Japan Study Group of NAFLD (JSG‐NAFLD). Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. J Gastroenterol 2021;56:1045-61. [PMID: 34718870 DOI: 10.1007/s00535-021-01833-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
69 Kemp W, Clayton-Chubb D, Majeed A, Glenister KM, Magliano DJ, Lubel J, Bourke L, Simmons D, Roberts SK. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study. J Gastroenterol Hepatol 2021. [PMID: 34693553 DOI: 10.1111/jgh.15723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
70 Cao W, Xu Y, Shen Y, Wang Y, Ma X, Bao Y. Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort. Diabetes Metab Syndr Obes 2021;14:4135-43. [PMID: 34616166 DOI: 10.2147/DMSO.S328206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Park H, Yoon EL, Kim M, Kim JH, Cho S, Jun DW, Nah EH. Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver. J Clin Med 2021;10:4625. [PMID: 34640643 DOI: 10.3390/jcm10194625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
72 Meroni M, Longo M, Paolini E, Lombardi R, Piciotti R, Francione P, Badiali S, Maggioni M, Fracanzani AL, Dongiovanni P. MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients. J Intern Med 2021. [PMID: 34605088 DOI: 10.1111/joim.13396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 George J, Gish RG, Geier A. MAFLD and Cardiovascular Events: What Does the Evidence Show? Clinical Gastroenterology and Hepatology 2021;19:2025-8. [DOI: 10.1016/j.cgh.2021.02.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
74 van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, Janssen HLA, de Knegt RJ, Sonneveld MJ. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep 2021;3:100350. [PMID: 34557660 DOI: 10.1016/j.jhepr.2021.100350] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
75 Zaiou M, Amrani R, Rihn B, Hajri T. Dietary Patterns Influence Target Gene Expression through Emerging Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease. Biomedicines 2021;9:1256. [PMID: 34572442 DOI: 10.3390/biomedicines9091256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
76 Spearman CW, Abdo A, Ambali A, Awuku YA, Kassianides C, Lesi OA, Ndomondo-Sigonda M, Onyekwere CA, Rwegasha J, Shewaye AB, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol 2021;6:1047-56. [PMID: 34508669 DOI: 10.1016/S2468-1253(21)00296-X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, Yang C, Zong G, Wu J, Jia W. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab 2021:dgab641. [PMID: 34508601 DOI: 10.1210/clinem/dgab641] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 22.0] [Reference Citation Analysis]
78 Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res 2021. [PMID: 34472683 DOI: 10.1111/hepr.13706] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
79 Pan Z, Fan JG, Eslam M. An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. Curr Opin Pharmacol 2021;60:170-6. [PMID: 34455284 DOI: 10.1016/j.coph.2021.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
80 Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2021. [PMID: 34459096 DOI: 10.1111/liv.15046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
81 Wong VW, Lazarus JV. Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change. J Hepatol 2021:S0168-8278(21)02015-8. [PMID: 34464658 DOI: 10.1016/j.jhep.2021.08.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
82 Wong GL, Yuen PC, Ma AJ, Chan AW, Leung HH, Wong VW. Artificial intelligence in prediction of non-alcoholic fatty liver disease and fibrosis. J Gastroenterol Hepatol 2021;36:543-50. [PMID: 33709607 DOI: 10.1111/jgh.15385] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
83 Hashida R, Nakano D, Yamamura S, Kawaguchi T, Tsutsumi T, Matsuse H, Takahashi H, Gerber L, Younossi ZM, Torimura T. Association between Activity and Brain-Derived Neurotrophic Factor in Patients with Non-Alcoholic Fatty Liver Disease: A Data-Mining Analysis. Life (Basel) 2021;11:799. [PMID: 34440543 DOI: 10.3390/life11080799] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
84 Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, Marcus C, Lee WS, Kelly D, Porta G, El-Guindi MA, Alisi A, Mann JP, Mouane N, Baur LA, Dhawan A, George J. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00183-7. [PMID: 34364544 DOI: 10.1016/S2468-1253(21)00183-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 47.0] [Reference Citation Analysis]
85 Chun HS, Kim MN, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle 2021. [PMID: 34337887 DOI: 10.1002/jcsm.12754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
86 Huang J, Xue W, Wang M, Wu Y, Singh M, Zhu Y, Kumar R, Lin S. MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis. Diabetes Metab Syndr Obes 2021;14:3417-25. [PMID: 34349535 DOI: 10.2147/DMSO.S316096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
87 Gaber Y, AbdAllah M, Salama A, Sayed M, Abdel Alem S, Nafady S. Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction. Expert Rev Gastroenterol Hepatol 2021;:1-9. [PMID: 34263707 DOI: 10.1080/17474124.2021.1952867] [Reference Citation Analysis]
88 Méndez-Sánchez N, Díaz-Orozco LE. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD). Med Sci Monit 2021;27:e933860. [PMID: 34248137 DOI: 10.12659/MSM.933860] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
89 Eslam M, Ahmed A, Després JP, Jha V, Halford JCG, Wei Chieh JT, Harris DCH, Nangaku M, Colagiuri S, Targher G, Joshi S, Byrne CD, Khunti K, Nguyen MH, Gish RG, George J. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol 2021;6:743-53. [PMID: 34265276 DOI: 10.1016/S2468-1253(21)00132-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 22.0] [Reference Citation Analysis]
90 Basaranoglu M, Kurtoglu A. Replacing the Name of NAFLD With a Metabolic or Another Forename as Indicator of the Era of Stagnation in NASH Studies. J Clin Gastroenterol 2021;55:548-9. [PMID: 33471489 DOI: 10.1097/MCG.0000000000001494] [Reference Citation Analysis]
91 Zhao J, Zhao Y, Hu Y, Peng J. Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease. Cell Mol Biol Lett 2021;26:32. [PMID: 34233623 DOI: 10.1186/s11658-021-00276-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
92 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
93 Yang RX, Zou ZS, Zhong BH, Deng H, He FP, Shi JP, Zhao CY, Mi YQ, Zhou YJ, Di FS, Zheng RD, Du Q, Shang J, Popovic B, Chen J, Fan JG. The pathologic relevance of metabolic criteria in patients with biopsy-proven non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00112-0. [PMID: 34246549 DOI: 10.1016/j.hbpd.2021.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
94 Wei JY, Xu Z, Li H, Du WQ, Niu BL, Li S, Tian S, Wu J, Chen YL, Li X, Liu ZL, Xiao J, Ren GS, Ran L, Kong LQ. Relationship between the Metabolic Associated Fatty Liver Disease and Endometrial Thickness in Postmenopausal Women: A Cross-sectional Study in China. Int J Med Sci 2021;18:3082-9. [PMID: 34400878 DOI: 10.7150/ijms.60780] [Reference Citation Analysis]
95 Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, Koseki M, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatol Res 2021. [PMID: 34129272 DOI: 10.1111/hepr.13685] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 36.0] [Reference Citation Analysis]
96 Mantovani A. MAFLD vs NAFLD: Where are we? Dig Liver Dis 2021;53:1368-72. [PMID: 34108096 DOI: 10.1016/j.dld.2021.05.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
97 Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00567-X. [PMID: 34033923 DOI: 10.1016/j.cgh.2021.05.029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 25.0] [Reference Citation Analysis]
98 Fukunaga S, Nakano D, Kawaguchi T, Eslam M, Ouchi A, Nagata T, Kuroki H, Kawata H, Abe H, Nouno R, Kawaguchi K, George J, Mitsuyama K, Torimura T. Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study. Int J Mol Sci 2021;22:5462. [PMID: 34067258 DOI: 10.3390/ijms22115462] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
99 Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, Dou X, Duan Z, Fan J, Gao Y, Han T, Han Y, Hu P, Huang Y, Huang Y, Jia J, Jiang J, Jiang Y, Li J, Li J, Li R, Li S, Li W, Li Y, Lin S, Liu J, Liu S, Lu L, Lu Q, Luo X, Ma X, Rao H, Ren H, Ren W, Shang J, Shi L, Su M, Wang B, Wang R, Wei L, Wen Z, Wu B, Wu J, Xin S, Xing H, Xu J, Yan M, Yang J, Yang J, Yang L, Yang Y, Yu Y, Zhang L, Zhang L, Zhang X, Zhang Y, Zhang Y, Zhao J, Zhao S, Zheng H, Zhou Y, Zhou Y, Zhuang H, Zuo W, Xu X, Qiao L. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol 2021;75:454-61. [PMID: 34019941 DOI: 10.1016/j.jhep.2021.05.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 36.0] [Reference Citation Analysis]
100 Mantovani A, Valenti L. A call to action for fatty liver disease. Liver Int 2021;41:1182-5. [DOI: 10.1111/liv.14907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
101 Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2021;32:500-14. [PMID: 33975804 DOI: 10.1016/j.tem.2021.04.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 33.0] [Reference Citation Analysis]
102 Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 2021;6:578-88. [PMID: 33961787 DOI: 10.1016/S2468-1253(21)00020-0] [Cited by in Crossref: 64] [Cited by in F6Publishing: 72] [Article Influence: 64.0] [Reference Citation Analysis]
103 Wai-sun Wong V, Kanwal F. On the Proposed Definition of Metabolic-Associated Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2021;19:865-70. [DOI: 10.1016/j.cgh.2021.01.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
104 Kim MN, Han K, Yoo J, Ha Y, Chon YE, Lee JH, Simon TG, Chan AT, Hwang SG. Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Sci Rep 2021;11:9154. [PMID: 33911167 DOI: 10.1038/s41598-021-88733-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
105 Eslam M, Ratziu V, George J. Yet more evidence that MAFLD is more than a name change. Journal of Hepatology 2021;74:977-9. [DOI: 10.1016/j.jhep.2020.12.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 16.0] [Reference Citation Analysis]
106 Kang SH, Cho Y, Jeong SW, Kim SU, Lee JW; Korean NAFLD Study Group. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Clin Mol Hepatol 2021;27:257-69. [PMID: 33751877 DOI: 10.3350/cmh.2021.0067] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 24.0] [Reference Citation Analysis]
107 Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int 2021;41:1290-3. [PMID: 33590934 DOI: 10.1111/liv.14828] [Cited by in Crossref: 70] [Cited by in F6Publishing: 79] [Article Influence: 70.0] [Reference Citation Analysis]
108 Dongiovanni P, Paolini E, Corsini A, Sirtori CR, Ruscica M. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. Eur J Clin Invest 2021;51:e13519. [PMID: 33583033 DOI: 10.1111/eci.13519] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 19.0] [Reference Citation Analysis]
109 Hatanaka T, Kakizaki S, Saito N, Nakano Y, Nakano S, Hazama Y, Yoshida S, Hachisu Y, Tanaka Y, Kashiwabara K, Yoshinaga T, Tojima H, Naganuma A, Uraoka T. Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study. Intern Med 2021;60:2167-74. [PMID: 33612679 DOI: 10.2169/internalmedicine.6574-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
110 Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, Ma Z, Bruno MJ, de Knegt RJ, Cao W, Peppelenbosch MP, Ghanbari M, Li Z, Pan Q. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00208-1. [PMID: 33618024 DOI: 10.1016/j.cgh.2021.02.030] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 29.0] [Reference Citation Analysis]
111 Eslam M, George J. MAFLD: Now is the time to capitalize on the momentum. J Hepatol 2021;74:1262-3. [PMID: 33587953 DOI: 10.1016/j.jhep.2021.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
112 Angelico F, Pastori D, Del Ben M. Impact of the New Metabolic-Associated Fatty Liver Disease (MAFLD) on NAFLD Patients Classification in Italy. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00149-X. [PMID: 33581358 DOI: 10.1016/j.cgh.2021.02.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
113 Huang J, Ou W, Wang M, Singh M, Liu Y, Liu S, Wu Y, Zhu Y, Kumar R, Lin S. MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease. Risk Manag Healthc Policy 2021;14:491-501. [PMID: 33603515 DOI: 10.2147/RMHP.S285880] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
114 Clayton M, Fabrellas N, Luo J, Alghamdi MG, Hafez A, Qadiri TA, Owise N, Attia D. From NAFLD to MAFLD: Nurse and allied health perspective. Liver Int 2021;41:683-91. [DOI: 10.1111/liv.14788] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 19.0] [Reference Citation Analysis]
115 Qiu K, Zhao Q, Wang J, Qi GH, Wu SG, Zhang HJ. Effects of Pyrroloquinoline Quinone on Lipid Metabolism and Anti-Oxidative Capacity in a High-Fat-Diet Metabolic Dysfunction-Associated Fatty Liver Disease Chick Model. Int J Mol Sci 2021;22:1458. [PMID: 33535680 DOI: 10.3390/ijms22031458] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
116 Wang MF, Wan B, Wu YL, Huang JF, Zhu YY, Li YB. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection. World J Gastroenterol 2021; 27(4): 336-344 [PMID: 33584066 DOI: 10.3748/wjg.v27.i4.336] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
117 Eslam M, George J. MAFLD: A game changer redefining fatty liver disease for adults and children. J Hepatol 2021;74:992-4. [PMID: 33453327 DOI: 10.1016/j.jhep.2021.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Eslam M, George J. MAFLD: A holistic view to redefining fatty liver disease. J Hepatol 2021;74:983-5. [PMID: 33453330 DOI: 10.1016/j.jhep.2020.12.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
119 Mendez-sanchez N, Arrese M, Gadano A, Oliveira CP, Fassio E, Arab JP, Chávez-tapia NC, Dirchwolf M, Torre A, Ridruejo E, Pinchemel-cotrim H, Castellanos Fernández MI, Uribe M, Girala M, Diaz-ferrer J, Restrepo JC, Padilla-machaca M, Dagher L, Gatica M, Olaechea B, Pessôa MG, Silva M. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. The Lancet Gastroenterology & Hepatology 2021;6:65-72. [DOI: 10.1016/s2468-1253(20)30340-x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 67.0] [Reference Citation Analysis]
120 Zheng KI, Sun DQ, Jin Y, Zhu PW, Zheng MH. Clinical utility of the MAFLD definition. J Hepatol 2021;74:989-91. [PMID: 33347953 DOI: 10.1016/j.jhep.2020.12.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
121 Lee H, Lee YH, Kim SU, Kim HC. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol 2021;19:2138-2147.e10. [PMID: 33348045 DOI: 10.1016/j.cgh.2020.12.022] [Cited by in Crossref: 93] [Cited by in F6Publishing: 76] [Article Influence: 46.5] [Reference Citation Analysis]
122 Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52. [PMID: 33270482 DOI: 10.1080/17474124.2021.1860019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
123 Fouad Y, Elwakil R, Elsahhar M, Said E, Bazeed S, Ali Gomaa A, Hashim A, Kamal E, Mehrez M, Attia D. The NAFLD-MAFLD debate: Eminence vs evidence. Liver Int 2021;41:255-60. [PMID: 33220154 DOI: 10.1111/liv.14739] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 19.0] [Reference Citation Analysis]
124 Schattenberg JM, Labenz C. Fatty liver disease – A multifaceted disease with more than one name? Liver Int 2020;40:2937-2938. [DOI: 10.1111/liv.14727] [Reference Citation Analysis]